Skip to main content
. 2022 Jun 15;132(12):e153580. doi: 10.1172/JCI153580

Figure 4. Anti-CD38 therapy depletes pathogenic ASCs in patients with ITP.

Figure 4

(A) Flow cytometric identification of circulating CD27+P63+ plasmablasts/plasma cells from patients D1 and D2 before (top panel) and 4 weeks after (bottom panel) the start of daratumumab (DARA) treatment. (B–G) Kinetic follow-up of patient D1 (B–D) and patient D2 (E–G) blood samples for (B and E) frequency of IgG-SCs among PBMCs and platelet levels. (C and F) Frequency of αIIbβ3-reactive IgG-SCs among PBMCs classified into high (red), medium (orange), and low (yellow) affinity. (D and G) Affinity for αIIbβ3 of single IgG-SCs. Displayed on the background is time spent in clinical remission (white) or relapse (gray). Daratumumab infusions are indicated by pink arrows. Single-cell affinity values and medians are plotted in D and G.